benefit 1
highdose 1
daunorubicin 1
aml 1
induction 1
extends 1
across 1
cytogenetic 1
molecular 1
groups 1
phase 1
ii 1
randomized 1
trial 2
comparing 1
standard 1
low 1
dose 1
rituximab 1
combined 1
alemtuzumab 1
initial 1
treatment 1
progressive 1
chronic 1
lymphocytic 1
leukemia 1
older 1
patients 2
ecogacrin 1
cancer 1
research 1
group 1
e 1
ph 1
complete 1
remission 1
similar 1
survival 1
reduced 1
intensity 1
myeloablative 1
allogeneic 1
transplantation 1
impact 1
tyrosine 1
kinase 1
inhibitor 1
minimal 1
residual 1
disease 1
